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From

Breakthrough
To Business
UNLV faculty discoveries have commercial applications
with value to the university, the private sector, and,
ultimately, you. Learn about three different faculty
members who are working to move their innovative
thinking out of the laboratory and into the boardroom.

Commercialization of faculty discoveries is on the rise at UNLV, facilitated by a new emphasis on
economic development associated with research, according to Thomas Piechota, interim vice
president for the recently renamed Division of Research and Economic Development.
“We want to bring greater attention to the important role the university plays in bringing
economic vitality and diversity to our community and state,” Piechota says, adding that
the university’s workforce development, business startup advising, and private-sector
partnerships all support this effort.
“But one of the principal ways we contribute to economic development is by supporting
commercialization of faculty discoveries through technology transfer,” he adds.
Technology transfer is the process through which the university’s discoveries, or
intellectual property, are transferred to another organization – typically in private industry –
for the purpose of development and commercialization. This activity has become increasingly
important to research universities across the country as they seek to contribute to economic
development in their communities and states while generating a valuable revenue stream.
Some notable results of the technology transfer process are Google and Gatorade, both
products originally invented in a university setting.
Technology transfer activity at UNLV has increased dramatically in recent years. The
university has filed 31 patent applications in the last four years; it has more than 140 research
disclosures on file and 14 issued patents listing UNLV inventors. Twenty-seven research
disclosures have been submitted in the last twelve months alone.
UNLV faculty have produced a wide variety of intellectual property with great
commercialization potential. Here are just a few of the most promising projects.
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Genome Surgery and xReader
Martin Schiller, Life Sciences Professor

E

ach week a group of students
gather in life sciences professor Martin Schiller’s bioinformatics lab to discuss what
they have been reading in
scientific journals.
It was here, in a nondescript room with
brown leather couches, where the idea for a
new approach to genome surgery was first
discussed. From this exchange, Schiller and
his team developed a novel idea combining
two technologies with bioinformatics tools
to remove disease-causing DNA from cells.
The discovery could lead to a new way to
treat HIV/AIDs.
UNLV recently submitted a patent application for this idea to the U.S. Patent Office, a
development of huge impact to Schiller.
“Unless someone else submitted an application for the exact thing before we did,
we may own a big advancement in medicine
at UNLV,” says Schiller, explaining his discovery with a short lesson on the way some
viruses interact with DNA.
“When a person is infected with some
pathogenic viruses, such as HIV, the virus inserts its DNA and becomes part of the DNA
of the infected cells,” he says, explaining
that patients receiving drug therapy may get
well temporarily, but the DNA of the virus
remains behind. Later, it can become reactivated, and the patient relapses.
“Latency is when you have the virus in
your genome, but it isn’t actively producing
infective virus,” says Schiller, who came to
UNLV in 2009 from the University of Connecticut School of Medicine. “This is the reason you can’t cure someone of AIDS. You can
lower the viral levels for a functional cure
as long as the person stays on a cocktail of
drugs the rest of their lives. But as soon as
you take them off the drugs, the virus explodes and mutates. At that point, the drugs
no longer work.”
Schiller notes that a technology exists
allowing researchers to specifically target
and cut out a region of DNA – which, he
reasoned, could be employed to fight latent
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HIV infection. But there is another pertinent
technology that emanates from HIV itself –
it is a protein that can actually travel across
cellular membranes; scientists have learned
how to harness the protein to deliver a
change to the interior of a cell.
“What we did is combine these two technologies,” says Schiller, “while taking advantage of our bioinformatics expertise.”
By “bioinformatics,” he is referring to his
laboratory’s tremendous amount of biological information on the human genome with
its 23,000 genes and resulting proteins. His
lab is known for its comprehensive database
on short contiguous peptide sequences that
are known to have a function in at least one
protein. Schiller credits an undergraduate
student in his lab, Horacio Guerra, with using this vast database and the Los Alamos
HIV sequence database to help identify the
right region to target in the HIV cells.
Schiller’s team analyzed thousands of
different HIV sequences and determined
parts in the HIV genome where a mutational
change is very rare, indicating that these are
critical genomic elements of HIV (and good
sites to target for intervention). Then, in the
laboratory, they designed a protein to enter
the cells of a person with a latent HIV infec-

tion, and snip out those parts of the genome,
effectively killing it.
In humans, blood stream injection
would be used to deliver this discovery. Because it has a portion of a protein from HIV
itself, it would move across cell membranes.
Still, Schiller acknowledges that much
additional work is needed before this technology will be approved for use in humans.
He notes that there are four stages of development to bring this product to market: The
first stage is to show that the protein works
in a test tube, which has been successfully
accomplished in his lab.
The second stage is to grow active HIV
cultures in the lab, and when this protein is
added, it should cure the infection in a dish
of cells. Schiller notes that Christy Strong, a
postdoctoral fellow in the lab, is currently
helping to shape this portion of the research.
The third and fourth steps are animal and
human trials, respectively.
Although confident of the viability of this
discovery, Schiller is aware of the difficulty in
bringing a new drug or technology to market.
“Only 1 in 500 of these types of applications ever lead to a drug,” he says. “This one
could fail along the way. Right now, it’s a
promising strategy, and we have some sound

Life sciences professor
Martin Schiller and his team
have designed a protein to
enter the cells of a person
with a latent HIV infection
and snip out critical parts
of the HIV genome.

indication that it has a chance of working.
“We have the hope that if this is successful
with the HIV virus, with adaptations to the system, it could work on almost anything – cancer,
immunological diseases, and more. There’s no
reason that this strategy can’t become a commonplace treatment for any disease.”
But if advancing a strategy that might
cure disease were not enough, Schiller has
also managed to develop another completely
different form of intellectual property with
great commercialization potential.
He has invented a new type of reading accelerator, called xReader, for which the university has filed another patent application.
The purpose of the tool is to make it easier
to read complicated documents, including scien-
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tific or legal journal articles that contain jargon.
“These types of documents often contain
words that are difficult to understand. With this
program, as you’re reading, and you don’t know
a word, you point to it and a definition pops up
along with relevant images.”
This would be useful for myriad circumstances, but particularly valuable for someone who has been recently diagnosed with
a disease and wants to learn more about it
from actual medical or research journals,
Schiller says.
“The xReader will enable you to better understand the jargon in order to make
more informed medical decisions.”
Schiller thought of the invention when
he was working with the huge amount of

bioinformatics data he and his team had collected for their research on genome surgery.
“I was thinking about ways in which we
could use the large data warehouse that we
built,” he says.
This invention is further along in the
commercialization process than the genome
surgery discovery, Schiller notes. Earlier this
year, the Schiller lab launched Taecan LLC, a
new startup company to advance the xReader in the marketplace. It will commercialize
the xReader technology, which is in the final stages of review by the U.S. Patent and
Trademark Office. Soon, the company will
be releasing several new mobile apps and
browser plug-ins for personal computers.
– Shane Bevell
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much shorter, the dots’ construction, calibration, and relative location must be carefully
considered for accurate and valid measurement,” Schill says. “The existing sensors
were too large and expensive for the work
we were doing. So, we came up with the idea
for the EM Dot out of pure necessity.”
Their breakthrough in electric and magnetic field sensor technology combines the
B and D dots into one sensor, creating a device resembling a wishbone that’s slightly
smaller than a regular paperclip.
“This single device measures both the
electric and magnetic fields at one point in
space simultaneously,” Schill says.
It was patented in 2009, and in 2013 the
technology was licensed to Kyma Technologies, Inc., a leading supplier of advanced
semiconductors, sensor technologies, and
other materials solutions that promote safety and energy efficiency.
Though Kyma has kept their plans for
the EM Dot mostly under wraps to maintain
their competitive business edge, Schill sees
various potential applications for the device.
One possible application he has researched focuses on leak detection in underground pipes. He used PVC piping to
mimic water transportation systems in order to find out how the EM Dot could be
used by water districts to pinpoint compro-

Engineering professor
Robert Schill has
developed a single device
that measures both
electric and magnetic
fields at one point in space
simultaneously.

EM Dot™

Robert Schill, Engineering Professor

A
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for racing tires.
And now comes the EM Dot, a novel
electric and magnetic sensor that will soon
have some innovative – and undoubtedly
unexpected – applications.
The EM Dot was developed by UNLV
electrical and computer engineering professor Bob Schill and his research associate,
Marc Popek, in 2005 to aid in their experiments with pulsed power in the Energy Materials Interaction Technology Initiative of
Nevada (EMITION) Center, located in the
Science and Engineering Building at UNLV.
Schill had previously acquired the Ne-

vada Shocker Pulse Power Machine, a one
million-volt, 100,000-to-200,000-ampere device that helped the researchers study the
interaction of pulsed power and materials.
But the team was stymied by a lack of the
right kind of field diagnostics for the machine. What existed at the time were two
separate field sensors: one was the B dot,
used to measure magnetic fields, and the
other was the D dot, which is used to measure electric fields.
“When you transition from the measurement of radio waves, which have very long
wavelengths, to micro waves, which are
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t first glance, it wouldn’t appear that the Post-it note, the
Kevlar vest, and the Electro
Magnetic (EM) Dot™ would
have much in common.
But dig a little deeper and you’d find
that they are all revolutionary inventions
originally intended for some other purpose.
For instance, the glue on Post-it notes,
which was once deemed capable of sticking nothing together reliably, was viewed
as ideal for attaching bookmarks in church
hymns. Before Kevlar became synonymous
with body armor, it was a material designed
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mised integrity of underground pipes. By
using an antenna inside the pipe at a fixed
position to send a pulse through the pipe,
Schill is able to receive readings with the
EM Dot at a fixed location external to the
pipe to detect and locate leaks.
This method – as opposed to using a
remote, submersible device propelled in
the pipe system that detects leaks based on
sound waves – has its benefits. It allows for
continuous monitoring over fixed locations
based on radio wave signals without acoustic noise signatures that are generated when
a shower is turned on or toilet is flushed.
While he has so far tested the technology on PVC piping only, Schill predicts that
this system would provide similar results in
metal and concrete pipes, particularly those
used in areas with hard water, such as Nevada. There is also potential to detect pipe
degradation with continuous monitoring,
especially in metal pipes, which would allow for preventive maintenance.
Since developing the EM Dot, Schill has
used it to conduct experiments for other
ongoing projects, including one started
in 2010 that will have military and/or law
enforcement applications. He calls it “the
detonator defeat system,” and it has the potential to disarm detonators of explosive devices without actual physical contact. The

system uses a coil that, when placed near
an improvised detonator, heats it up to the
point of controlling or confounding the
mechanism that detonates the blast. The
university filed a patent application on the
technology this year.
The device could be invaluable in locating and “defeating” improvised explosive
devices (IEDs) that caused so many horrendous injuries and fatalities among military
personnel in Iraq and other countries.
What makes Schill’s system unique is
its non-specificity to devices and its ability
to impact various materials.
“The difficult thing with improvised
detonators,” Schill says, “is that you essentially have a black box, and you don’t know
what’s in it. You don’t know what has been
used to build the detonator, and each possibility – tungsten, platinum, copper, etc. –
has its own fingerprint. Moreover, one does
not know a priori the connecting circuitry
to activate the detonator. We’ve conducted
numerous experiments with different materials and connecting circuit loading effects, and we found similarities in results,
pointing to the device’s ability to perform
in all scenarios.”
In its current state, the coil is relatively
small, and it requires an individual or a robot to place it so close to a detonator that its
exact location must be known. As he continues work on the system, Schill hopes to
extend its size to cover wider areas, eliminating the need to know a detonator’s location, and to implement a detection system
that would allow for potential disarmament
of underground mines on the battlefield.
In addition to inventing several technologies, Schill has also founded and directed the EMITION Center and performed
countless hours of research. Since 2005, his
center has been home to ground-breaking
work on initiatives that he hopes will one
day enable UNLV to become more competitive in conducting research in novel areas
that are beneficial and pertinent to the state
and the nation.
– Shannon Spollen
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C. diff Prevention

Chemistry professor
Ernesto Abel-Santos has
discovered a compound
that that keeps C. diff
spores from germinating.

Ernesto Abel -Santos, Chemistry Professor
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are basically out of pharmacological options.
Other options are not pleasant and include
a colectomy, which involves cutting out the
infected intestine, or fecal transplantation,
which replenishes the good bacteria in your
intestinal tract.”
The problem is that while antibiotics kill
the bacteria that are causing bronchitis or
other infections, they also kill the good bacteria in your body, and that is when C. diff
introduces itself.
What Abel-Santos discovered is a compound that basically functions the same way
the good intestinal bacteria does: It keeps
the C. diff spores from germinating, acting
as a surrogate for gut bacteria and thereby
preventing infection.
Abel-Santos’ path to this discovery emanated from his research in the area of bacterial spores, anthrax being the most famous.
He became interested in bacterial spores
after the Sept. 11 terror attacks when letters containing anthrax spores were mailed
to several news media offices and two U.S.
Senators, killing five people and infecting
17 others.
Clostridium difficile is another bacteria
that forms spores. “The problem with these
types of bacteria is that when you try to kill

them, instead of dying, they form a very resistant structure,” he says.
The resistant spores stay in the environment or body for a long time and, under the right conditions, can germinate,
producing toxins and infecting those who
are vulnerable.
Abel-Santos studies that germination process. “We want to understand how a dormant
spore can detect its environment. It has to be
able to figure out when it is sitting on a desk
contaminating a surface and differentiate
that from when it is inside your body.”
He explains that bacterial spores use
signals from the environment to germinate – typically substances found inside the
body, such as amino acids and sugars. So
Abel-Santos and his team made molecules
to mimic the signals that the bacteria use to
trigger germination. Once they were able to
make compounds that mimic these types of
biomolecules, they were then able to make
compounds that inhibit them. These inhibitors are then able to block the spore from
germinating. If the spore germination is
blocked, then the spore passes through the
body without producing toxins.
So far, the compound has proven successful in animal models, though his studies
continue. Eventually, the team will plan for
testing of the compound’s effect on humans,
though much work is necessary before that
phase of the research is pursued.
Someday, Abel-Santos says, his discovery
could be prescribed as a prophylactic measure for those likely to be troubled by C. diff,
as the drug is designed to prevent infection
rather than treat it.
“The idea is that patients will be given
the anti-germinant at the same time as other
antibiotics, so that even if they are infected
with the spore, this compound will keep the
spore from germinating,” he says. “If they
don’t germinate, they don’t produce toxins.
And once you finish the antibiotic treatment, your gut bacteria are going to come
back, which will allow you to stop the antigerminant treatment.”
– Shane Bevell
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magine the following scenario:
You go to the hospital for bronchitis or another ailment. You are
prescribed an antibiotic and start
feeling better, but you suddenly get
severe abdominal pain and uncontrollable
diarrhea. You go back to the doctor and
learn that you now have a different, secondary infection. The doctor takes you off the
bronchitis medication and gives you a new
antibiotic that targets the secondary infection. You start feeling relief from the diarrhea, but the bronchitis returns. Now the
doctor stops the second medication to start
treating the bronchitis again.
This vicious cycle continues and can
eventually become very serious, even deadly.
The secondary infection in the above
scenario is from the bacterium Clostridium
difficile (C. diff). In the United States alone,
there are approximately 500,000 cases and
20,000 deaths each year as a result of it. Illness from C. diff typically occurs after use
of antibiotics and often affects patients who
have suppressed immune systems, many
of whom have been in a hospital, nursing
home, surgery center, or similar facility
where C. diff is present.
However, all hope isn’t lost for those
who are exposed to this infection. UNLV
biochemistry professor Ernesto Abel-Santos
and his team of students believe they have
found a potential solution.
The university shares their belief in the
value of the treatment and has pursued a
patent for his discovery through the U.S.
Patent and Trademark Office. He also has cofounded Abel Therapeutics LLC to develop
a new drug for preventing C. diff. Additionally, he has worked with College of Business
entrepreneurship students, who developed
a business plan for his company. The team
won second place at the Southern Nevada
Business Plan Competition.
“There are really only two drugs that treat
the Clostridium difficile infection,” says AbelSantos, who came to UNLV in 2006 from the
Albert Einstein College of Medicine in New
York City. “So after the second relapse, you
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